Resource utilization in patients with schizophrenia who initiated risperidone long-acting therapy: results from the Schizophrenia Outcomes Utilization Relapse and Clinical Evaluation (SOURCE)

被引:31
作者
Crivera, Concetta [1 ]
DeSouza, Cherilyn [2 ]
Kozma, Chris M. [3 ]
Dirani, Riad D. [4 ]
Mao, Lian [5 ]
Macfadden, Wayne [4 ]
机构
[1] Janssen Sci Affairs LLC, Raritan, NJ USA
[2] Vet Affairs Med Ctr, Kansas City, MO USA
[3] Univ S Carolina, Columbia, SC 29208 USA
[4] Janssen Sci Affairs LLC, Titusville, NJ USA
[5] Johnson & Johnson Pharmaceut Res & Dev LLC, Titusville, NJ USA
关键词
INJECTABLE RISPERIDONE; UNITED-STATES; MIRROR-IMAGE; OPEN-LABEL; INJECTION; CARE; EFFICACY; SAFETY; TRIAL; COSTS;
D O I
10.1186/1471-244X-11-168
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Background: Schizophrenia is a chronic mental health disorder associated with increased hospital admissions and excessive utilization of outpatient services and long-term care. This analysis examined health care resource utilization from a 24-month observational study of patients with schizophrenia initiated on risperidone long-acting therapy (RLAT). Methods: Schizophrenia Outcomes Utilization Relapse and Clinical Evaluation (SOURCE) was a 24-month observational study designed to examine real-world treatment outcomes by prospectively following patients with schizophrenia initiated on RLAT. At baseline visit, prior hospitalization and ER visit dates were obtained for the previous 12 months and subsequent hospitalization visit dates were obtained at 3-month visits, if available. The health care resource utilization outcomes measures observed in this analysis were hospitalizations for any reason, psychiatric-related hospitalizations, and emergency room (ER) visits. Incidence density analysis was used to assess pre-event and postevent rates per person-year (PY). Results: The primary medical resource utilization analysis included 435 patients who had a baseline visit, >= 1 postbaseline visits after RLAT initiation, and valid hospitalization dates. The number of hospitalizations and ER visits per PY declined significantly (p < .0001) after initiation with RLAT. A 41% decrease (difference of -0.29 hospitalizations per PY [95% CI: -0.39 to -0.18] from baseline) in hospitalizations for any reason, a 56% decrease (a difference of -0.35 hospitalizations per PY [95% CI: -0.44 to -0.26] from baseline) in psychiatric-related hospitalizations, and a 40% decrease (-0.26 hospitalizations per PY [95% CI: -0.44 to -0.10] from baseline) in ER visits were observed after the baseline period. The percentage of psychiatric-related hospitalizations decreased significantly after RLAT initiation, and patients had fewer inpatient hospitalizations and ER visits (all p < .0001). Conclusion: The results suggest that treatment with RLAT may result in decreased hospitalizations for patients with schizophrenia.
引用
收藏
页数:6
相关论文
共 21 条
[1]   Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets [J].
Chue, P ;
Eerdekens, M ;
Augustyns, I ;
Lachaux, B ;
Molcan, P ;
Eriksson, L ;
Pretorius, H ;
David, AS .
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2005, 15 (01) :111-117
[2]  
Conley Robert R, 2003, Ann Clin Psychiatry, V15, P23, DOI 10.1023/A:1023276509470
[3]   Long-acting injectable risperidone [J].
Ehret, MJ ;
Fuller, MA .
ANNALS OF PHARMACOTHERAPY, 2004, 38 (12) :2122-2127
[4]   Treatment of schizophrenia with long-acting injectable risperidone: A 12-month open-label trial of the first long-acting second-generation antipsychotic [J].
Fleischhacker, WW ;
Eerdekens, M ;
Karcher, K ;
Remington, G ;
Llorca, PM ;
Chrzanowski, W ;
Martin, S ;
Gefvert, O .
JOURNAL OF CLINICAL PSYCHIATRY, 2003, 64 (10) :1250-1257
[5]  
Fuller M, 2009, J Med Econ, V12, P317, DOI 10.3111/13696990903303902
[6]   Relapse Prevention in Schizophrenia and Schizoaffective Disorder with Risperidone Long-Acting Injectable vs Quetiapine: Results of a Long-Term, Open-Label, Randomized Clinical Trial (vol 35, pg 2367, 2010) [J].
Gaebel, Wolfgang ;
Schreiner, Andreas ;
Bergmans, Paul ;
de Arce, Rosario ;
Rouillon, Frederic ;
Cordes, Joachim ;
Eriksson, Lars ;
Smeraldi, Enrico .
NEUROPSYCHOPHARMACOLOGY, 2011, 36 (02) :548-548
[7]   Relapse Prevention in Schizophrenia and Schizoaffective Disorder with Risperidone Long-Acting Injectable vs Quetiapine: Results of a Long-Term, Open-Label, Randomized Clinical Trial [J].
Gaebel, Wolfgang ;
Schreiner, Andreas ;
Bergmans, Paul ;
de Arce, Rosario ;
Rouillon, Frederic ;
Cordes, Joachim ;
Eriksson, Lars ;
Smeraldi, Enrico .
NEUROPSYCHOPHARMACOLOGY, 2010, 35 (12) :2367-2377
[8]   Long-acting injectable risperidone: Efficacy and safety of the first long-acting atypical antipsychotic [J].
Kane, JM ;
Eerdekens, M ;
Lindenmayer, JP ;
Keith, SJ ;
Lesem, M ;
Karcher, K .
AMERICAN JOURNAL OF PSYCHIATRY, 2003, 160 (06) :1125-1132
[9]   Effectiveness of risperidone long-acting injection in first-episode schizophrenia: In naturalistic setting [J].
Kim, Borah ;
Lee, Sang-Hyuk ;
Choi, Tae Kyou ;
Suh, ShinYoung ;
Kim, Yong Woo ;
Lee, EunHee ;
Yook, Ki Hwan .
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2008, 32 (05) :1231-1235
[10]   Healthcare resource utilization during 1-year treatment with long-acting, injectable risperidone [J].
Leal, A ;
Rosillon, D ;
Mehnert, A ;
Jarema, M ;
Remington, G .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2004, 13 (11) :811-816